Lutz P. Muller

Ernst Grube Str. 40
Halle, NI 06120, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 67 publications

Allogeneic stem cell transplantation after myeloablative conditioning with fludarabine, thiotepa, and cyclophosphamide in relapsed or refractory aggressive B-cell and T-cell lymphomas: results of the prospective ASTRAL study.

Allogeneic stem cell transplantation after myeloablative conditioning with fludarabine, thiotepa, and cyclophosphamide in relapsed or refractory aggressive B-cell and T-cell lymphomas: results of the prospective ASTRAL study.

Journal: Haematologica
Published: February 04, 2026

Author Correction: Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Author Correction: Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Journal: Nature medicine
Published: January 07, 2026

What is the best path towards allogeneic transplantation in MDS and AML? A survey among German-spreaking centers for allogeneic hematopoietic stem cell transplantation.

What is the best path towards allogeneic transplantation in MDS and AML? A survey among German-spreaking centers for allogeneic hematopoietic stem cell transplantation.

Journal: Annals of hematology
Published: December 23, 2025

Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Journal: Blood
Published: October 14, 2025

Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Journal: Blood
Published: October 14, 2025

CAR-DLI for ALL, but not without lymphodepletion.

CAR-DLI for ALL, but not without lymphodepletion.

Journal: Blood
Published: October 02, 2025

Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.

Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.

Journal: Leukemia
Published: April 03, 2025

Stromal Cells in Early Inflammation-Related Pancreatic Carcinogenesis-Biology and Its Potential Role in Therapeutic Targeting.

Stromal Cells in Early Inflammation-Related Pancreatic Carcinogenesis-Biology and Its Potential Role in Therapeutic Targeting.

Journal: Cancers
Published: April 03, 2025

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.

Journal: Blood
Published: February 07, 2025

Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings.

Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings.

Journal: Leukemia
Published: February 04, 2025

Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.

Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.

Journal: Transplantation and cellular therapy
Published: December 08, 2024

Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysis.

Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysis.

Journal: Bone marrow transplantation
Published: August 04, 2024
Showing 1-12 of 67

Last Updated: 09/26/2026